Intra-Cellular Therapies (ITCI) Tops Q4 Loss Expectations

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.67), $0.23 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $30.66 million versus the consensus estimate of $60 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen